Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …

Opinion statement At this time, there are no FDA-approved immune therapies for
glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a …

Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system,
characterized by an extremely aggressive clinical phenotype. Patients with GBM have a …

Glioma is one of the most common malignant tumors of the central nervous system and is
characterized by extensive infiltrative growth, neovascularization, and resistance to various …

Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …

Glioblastomas are heterogeneous neoplasms that are driven by complex signalling
pathways, and are among the most aggressive and challenging cancers to treat. Despite …

The promise of dendritic cell (DC)–based immunotherapy has been established by two
decades of translational research. Of the four malignancies most targeted with clinical DC …

Glioma is the most malignant primary tumor of the central nervous system and is
characterized by an extremely low overall survival. Recent breakthroughs in cancer therapy …

Background Outcomes for patients with recurrent glioblastoma multiforme (GBM) are poor
and may be improved by immunotherapy. We investigated the safety and efficacy of an …

Isocitrate dehydrogenases (IDH) 1 and 2 are key metabolic enzymes that generate reduced
nicotinamide adenine dinucleotide phosphate (NADPH) to maintain a pool of reduced …